Abstract
Derived from proopiomelanocortin by proteolytic processing, melanocortins have been implicated in a wide range of physiological processes. Melanocortins exert their physiological effects by binding to specific receptors on the surface of cell membranes. To date, five subtypes of melanocortin receptors (MC1 - MC5) have been identified, all of which are G-protein coupled receptor whose activation leads to increase in intracellular cyclic 3,5-adenosine monophosphate formation. Of these, the MC4 receptor is expressed predominantly throughout the central nervous system, particularly, in areas related to stress responses and emotional states. Expression of the MC4 receptor is regulated by stress exposure. Reports also indicate that stimulation of the MC4 receptor activates the hypothalamus-pituitary-adrenal axis, and that the MC4 receptor mediates stress-related behaviors and anxiety in rodents. Recently developed selective MC4 receptor antagonists have demonstrated antidepressant and anxiolytic effects in several animal models of depression and anxiety. MC4 receptor antagonists are effective, particularly under conditions of high stress, which may be consistent with the etiology of depression and anxiety. This review describes the involvement of the MC4 receptor in stress response and discusses the potential value of MC4 receptor antagonists for the treatment of stress-related disorders such as depression and anxiety.
Keywords: mc4 receptor, melanocortin, antidepressant, anxiolytic, depression, anxiety, hypothalamus-pituitary-adrenal axis
Current Topics in Medicinal Chemistry
Title: Melanocortin-4 Receptor Antagonists for the Treatment of Depression and Anxiety Disorders
Volume: 7 Issue: 11
Author(s): Taketoshi Okubo and Shigeyuki Chaki
Affiliation:
Keywords: mc4 receptor, melanocortin, antidepressant, anxiolytic, depression, anxiety, hypothalamus-pituitary-adrenal axis
Abstract: Derived from proopiomelanocortin by proteolytic processing, melanocortins have been implicated in a wide range of physiological processes. Melanocortins exert their physiological effects by binding to specific receptors on the surface of cell membranes. To date, five subtypes of melanocortin receptors (MC1 - MC5) have been identified, all of which are G-protein coupled receptor whose activation leads to increase in intracellular cyclic 3,5-adenosine monophosphate formation. Of these, the MC4 receptor is expressed predominantly throughout the central nervous system, particularly, in areas related to stress responses and emotional states. Expression of the MC4 receptor is regulated by stress exposure. Reports also indicate that stimulation of the MC4 receptor activates the hypothalamus-pituitary-adrenal axis, and that the MC4 receptor mediates stress-related behaviors and anxiety in rodents. Recently developed selective MC4 receptor antagonists have demonstrated antidepressant and anxiolytic effects in several animal models of depression and anxiety. MC4 receptor antagonists are effective, particularly under conditions of high stress, which may be consistent with the etiology of depression and anxiety. This review describes the involvement of the MC4 receptor in stress response and discusses the potential value of MC4 receptor antagonists for the treatment of stress-related disorders such as depression and anxiety.
Export Options
About this article
Cite this article as:
Taketoshi Okubo and Shigeyuki Chaki , Melanocortin-4 Receptor Antagonists for the Treatment of Depression and Anxiety Disorders, Current Topics in Medicinal Chemistry 2007; 7 (11) . https://dx.doi.org/10.2174/156802607780906618
DOI https://dx.doi.org/10.2174/156802607780906618 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Dysfunction: Methods of Assessment & Implications for Cardiovascular Diseases
Current Pharmaceutical Design Torasemide for the Treatment of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Potential Role of Inflammation in Associations between Particulate Matter and Heart Failure
Current Pharmaceutical Design Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Current Pharmaceutical Design Current Place of Beta-Blockers in the Treatment of Hypertension
Current Vascular Pharmacology The anti-inflammatory agents Siblings Nitroxyl (HNO) and Nitric Oxide (NO) in Cardioprotection
Drug Design Reviews - Online (Discontinued) Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Current Hypertension Reviews Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology Medico-Legal Evaluation of Fatal Perinatal Asphyxia
Current Pediatric Reviews Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews Role of Magnetic Resonance Imaging in Myocardial Iron Assessment
Current Cardiology Reviews Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) Resistin and Cardiovascular Disease: A Review of the Current Literature Regarding Clinical and Pathological Relationships
Current Cardiology Reviews Energy Metabolism, Adult Neurogenesis and their Possible Roles in Alzheimer’s Disease: A Brief Overview
Current Topics in Medicinal Chemistry Innate Immune Inflammatory Response in the Acutely Ischemic Myocardium
Medicinal Chemistry Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews The Influence of Obese Insulin-Resistance on the Outcome of the Ischemia/Reperfusion Insult to the Heart
Current Medicinal Chemistry ATP-Sensitive K+ Channels: Current and Putative Target for the Prevention and Treatment of Cardiovascular Diseases
Vascular Disease Prevention (Discontinued) Therapeutic Potential of Endothelial Progenitor Cells for Cardiovascular Diseases
Current Vascular Pharmacology